Triple-negative breast cancer is characterized by impaired expression of progesterone and estrogen receptors and human epidermal growth factor receptor 2 (HER2), making it aggressive and unresponsive to targeted therapies (3). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.